IP Library Granted Patent US 10,046,034
Granted Patent B2
US 10,046,034 · App. 15/465,408 · Granted Aug 14, 2018

Hemostatic compositions

Inventors: Christian Gagnieu (Chassieu, FR); Patricia Forest (Lyons, FR); Sylvain Picot (Lyons, FR)
Assignee: BIOM'UP
A61K38/4833A61K9/14A61K31/726A61K38/36A61K38/39A61K47/26A61L26/0033C12Y304/21005A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,046,034
App. No.
15/465,408
Granted
Aug 14, 2018
Kind
B2
Abstract

The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.

Claims (37)

1. A hemostatic composition in powder form comprising:

collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, said collagen being in a content ranging from 70% to 99% by weight relative to the total weight of the composition,

at least one monosaccharide in a content ranging from 1% to 12.5% by weight relative to the total weight of the composition, and

at least one coagulation factor in a content ranging from 0.01 IU/mg to 20 IU/mg of the composition.

2. The composition of claim 1 , wherein said composition comprises a collagen content ranging from 75% to 96% by weight relative to the total weight of the composition.

3. The composition of claim 1 , wherein said composition comprises a collagen content ranging from 77% to 93% by weight relative to the total weight of the composition.

4. The composition of claim 1 , wherein said composition comprises a collagen content ranging from 80% to 90% by weight relative to the total weight of the composition.

5. The composition of claim 1 , wherein said composition comprises a monosaccharide content ranging from 1.5% to 10% by weight relative to the total weight of the composition.

6. The composition of claim 1 , wherein said composition comprises a monosaccharide content ranging from 2% to 8% by weight relative to the total weight of the composition.

7. The composition of claim 1 , wherein said composition comprises a monosaccharide content ranging from 2.5% to 7.5% by weight relative to the total weight of the composition.

8. The composition of claim 1 , wherein said composition comprises a collagen/monosaccharide weight ratio ranging from 10 to 50.

9. The composition of claim 1 , wherein the collagen comprises a content of fibrous collagen and/or fibrillar collagen ranging from 85% to 95% by weight relative to the total weight of the collagen.

10. The composition of claim 1 , wherein said composition further comprises a glycosaminoglycan in a content ranging from 2% to 25% by weight relative to the total weight of the composition.

11. The composition of claim 10 , wherein the glycosaminoglycan is chosen among chondroitin sulfate, dermatan sulfate, hyaluronic acid and mixtures thereof.

12. The composition of claim 1 , wherein said composition further comprises a glycosaminoglycan, wherein the collagen/total carbohydrate compounds weight ratio ranging from 2 to 40, wherein the weight of the total carbohydrate compounds is the sum of the weight of the monosaccharide(s) and the weight of the glycosaminoglycan(s).

13. The composition of claim 1 , wherein said composition comprises a coagulation factor in a content ranging from 0.05 IU/mg to 10 IU/mg of the composition.

14. The composition of claim 1 , wherein said composition comprises a coagulation factor in a content ranging from 0.1 IU/mg to 5 IU/mg of the composition.

15. The composition of claim 1 , wherein said composition comprises a coagulation factor in a content ranging from 0.2 IU/mg to 2 IU/mg of the composition.

16. The composition of claim 1 , wherein the at least one coagulation factor is thrombin.

17. The composition of claim 1 , wherein said composition has a tapped density greater than 0.4 g/mL.

18. The composition of claim 1 , wherein said composition comprises at least 50% by weight of particles whose size is between 200 μm and 400 μm.

19. The composition of claim 1 , wherein said composition comprises a collagen/monosaccharide weight ratio of 19.

20. A kit comprising:

the composition of claim 1 , and

a spraying device.

21. A method for preparing a hemostatic composition according to claim 1 , comprising at least the following steps:

a) formation of an aqueous suspension comprising a collagen of fibrillar type having a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, with a collagen content ranging from 70% to 99% by weight relative to the total weight of the composition and a monosaccharide content ranging from 1% to 12.5% by weight relative to the total weight of the composition,

b) recovery of the product in the form of precipitate, paste or gel,

c) drying of the product,

d) grinding of the product to the desired granulometry,

e) adding at least one coagulation factor in a content ranging from 0.01 IU/mg to 20 IU/mg.

22. The method of claim 21 , wherein in the step b) the recovery of the product is carried by centrifugation or decantation.

23. The method of claim 21 , wherein the collagen used in step a) is obtained by basic extraction.

24. The method of claim 21 , wherein the coagulation factor is thrombin.

25. The method of claim 21 , wherein in step e) is further added at least one glycosaminoglycan.

26. A method of treating a patient with a wound, comprising:

administering the composition of claim 1 to the patient in need thereof.

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2023
From: BIOM'UP FRANCE SAS
To: DILON TECHNOLOGIES INC.
Reel/Frame 063779/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: BIOM'UP
To: BIOM'UP FRANCE SAS
Reel/Frame 055292/0061 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 050600/0634 Recorded Jul 20, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: BIOM'UP
Reel/Frame 053259/0349 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 050008/0859 Recorded Jul 20, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: BIOM'UP
Reel/Frame 053259/0653 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 045460/0084 AND 045865/0851 Recorded Jul 20, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: BIOM'UP
Reel/Frame 053259/0309 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 049816/0205 Recorded Jul 20, 2020
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: BIOM'UP
Reel/Frame 053259/0334 →
SECURITY INTEREST Recorded Oct 2, 2019
From: BIOM'UP
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 050600/0634 →
SECURITY INTEREST Recorded Aug 9, 2019
From: BIOM'UP
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP, AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 050008/0859 →
SECURITY INTEREST Recorded Jul 22, 2019
From: BIOM'UP
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP, AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 049816/0205 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 045460 FRAME: 0084. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Apr 9, 2018
From: BIOM'UP
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP, AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 045865/0851 →
SECURITY INTEREST Recorded Apr 6, 2018
From: BIOM'UP
To: ATHYRIUM OPPORTUNIIES III ACQUISITION LP, AS BONDHOLDERS' REPRESENTATIVE
Reel/Frame 045460/0084 →
Priority Claims (1)
EP 11305492 · Apr 27, 2011 · regional
Continuity (4)
Continuation 15048647 · Feb 19, 2016
Continuation 14007798
Provisional Application 61517973 · Apr 27, 2011
Related Publication 20170189499A1 · Jul 6, 2017